Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2017 Summary According to the recently published report 'Histone Deacetylase 3 - Pipeline Review, H2 2017'; Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zinc-finger transcription factor YY1. This protein can also down-regulate p53 function and thus modulate cell growth and apoptosis. The report 'Histone Deacetylase 3 - Pipeline Review, H2 2017' outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 1, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Dermatology, Gastrointestinal, Genetic Disorders, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Follicular Lymphoma, Non-Small Cell Lung Cancer, Melanoma, Myelodysplastic Syndrome, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Metastatic Renal Cell Carcinoma, Non-Hodgkin Lymphoma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Alopecia, Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), CNS Lymphoma, Cutaneous T-Cell Lymphoma, Drug Addiction, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lung Adenocarcinoma, Lung Cancer, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Neurodegenerative Diseases, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Post-Traumatic Stress Disorder (PTSD), Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Soft Tissue Sarcoma, T-Cell Leukemia and Thyroid Cancer. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - The report reviews Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects - The report assesses Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Overview 7 Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 15 Products under Development by Universities/Institutes 21 Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Assessment 23 Assessment by Mechanism of Action 23 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 28 4SC AG 28 Chipscreen Biosciences Ltd 28 Curis Inc 29 HitGen LTD 30 IRBM Science Park SpA 30 Medivir AB 31 Merck & Co Inc 31 Sigma-Tau SpA 32 Syndax Pharmaceuticals Inc 32 Zhejiang Hisun Pharmaceutical Co Ltd 33 Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Drug Profiles 35 4SC-202 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 CUDC-907 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Drug to Inhibit HDAC-3 for Oncology - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 entinostat - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 HG-3001 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 KDAC-0001 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 largazole - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 remetinostat - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 ST-3595 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 tucidinostat - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 vorinostat - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Dormant Products 71 Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Product Development Milestones 73 Featured News & Press Releases 73 Jul 11, 2017: Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy 73 May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 73 May 17, 2017: Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Advanced Melanoma 74 May 16, 2017: Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies 75 Apr 20, 2017: Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting 76 Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer 76 Apr 11, 2017: New mechanistic insights into 4SC-202's epigenetic mode of action 77 Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma 78 Jan 05, 2017: Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors 79 Nov 08, 2016: Syndax Pharmaceuticals to Present Data On Entinostat at the SITC 31st Annual Scientific Meeting 79 Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 80 Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 80 May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting 81 Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting 82 Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 83 Appendix 84 Methodology 84 Coverage 84 Secondary Research 84 Primary Research 84 Expert Panel Validation 84 Contact Us 84 Disclaimer 85
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indications, H2 2017 10 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13 Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 14 Number of Products under Development by Companies, H2 2017 15 Products under Development by Companies, H2 2017 16 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 20 Number of Products under Investigation by Universities/Institutes, H2 2017 21 Products under Investigation by Universities/Institutes, H2 2017 22 Number of Products by Stage and Mechanism of Actions, H2 2017 23 Number of Products by Stage and Route of Administration, H2 2017 25 Number of Products by Stage and Molecule Type, H2 2017 27 Pipeline by 4SC AG, H2 2017 28 Pipeline by Chipscreen Biosciences Ltd, H2 2017 29 Pipeline by Curis Inc, H2 2017 30 Pipeline by HitGen LTD, H2 2017 30 Pipeline by IRBM Science Park SpA, H2 2017 31 Pipeline by Medivir AB, H2 2017 31 Pipeline by Merck & Co Inc, H2 2017 32 Pipeline by Sigma-Tau SpA, H2 2017 32 Pipeline by Syndax Pharmaceuticals Inc, H2 2017 33 Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017 34 Dormant Products, H2 2017 71 Dormant Products, H2 2017 (Contd..1), H2 2017 72
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
